FDA Approves NEXPLANON — Organon LLC

Organon LLC reported the U.S. Food and Drug Administration's approval of its subcutaneous implantable contraceptive, NEXPLANON, marking a pivotal expansion for the etonogestrel market. This regulatory clearance is expected to drive continued growth and competitive positioning for the Organon within the long-acting reversible contraception sector.